Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma
Komber`yati P., McCormack K., Malka-Rais J., Spahn J. D.
Journal of Allergy and Clinical Immunology: In Practice
Vol.7, Issue8, P. 2689-2696.e2
Опубликовано: 2019
Тип ресурса: Статья
DOI:10.1016/j.jaip.2019.05.053
Аннотация:
Background: Mepolizumab is an anti–IL-5 antibody approved for the treatment of severe eosinophilic asthma. However, the prevalence of patients with severe asthma eligible for mepolizumab remains unknown, especially among children. Objective: To determine, in a population of patients with severe asthma from a tertiary referral center, the proportion of patients with an eosinophilic phenotype who would be eligible for mepolizumab, when stratified for the age of onset of asthma, and the prevalence of phenotypic features that favor mepolizumab therapy. Methods: An extensive database of 245 adults and children referred for severe asthma was used. The prevalence of severe asthma was estimated by using the European Respiratory Society/American Thoracic Society criteria. Patients with an eosinophilic uncontrolled phenotype qualified for mepolizumab. Results: In our cohort, 216 (88[%]) had severe asthma. Based on blood eosinophils of either greater than or equal to 150 cells/μL or greater than or
Ключевые слова:
Adult; Adult-onset; Childhood-onset; Children; Corticosteroid; Eosinophil; IL-5; Mepolizumab; Prevalence; Severe asthma
mepolizumab; steroid; adult; age; Article; asthma; child; cohort analysis; controlled study; disease exacerbation; female; forced expiratory flow; forced expiratory volume; forced vital capacity; human; human cell; major clinical study; male; nose polyp; onset age; prevalence; retrospective study; tertiary care center
Язык текста: Английский
ISSN: 2213-2201
Komber`yati P. Paskuale 1988-
McCormack K.
Malka-Rais J.
Spahn J. D.
Комберьяти П. Паскуале 1988-
МcCормаcк К.
Малка-Раис Й.
Спахн Й. Д.
Proportion of Severe Asthma Patients Eligible for Mepolizumab Therapy by Age and Age of Onset of Asthma
Текст визуальный непосредственный
Journal of Allergy and Clinical Immunology: In Practice
Vol.7, Issue8 P. 2689-2696.e2
2019
Статья
Adult Adult-onset Childhood-onset Children Corticosteroid Eosinophil IL-5 Mepolizumab Prevalence Severe asthma
mepolizumab steroid adult age Article asthma child cohort analysis controlled study disease exacerbation female forced expiratory flow forced expiratory volume forced vital capacity human human cell major clinical study male nose polyp onset age prevalence retrospective study tertiary care center
Background: Mepolizumab is an anti–IL-5 antibody approved for the treatment of severe eosinophilic asthma. However, the prevalence of patients with severe asthma eligible for mepolizumab remains unknown, especially among children. Objective: To determine, in a population of patients with severe asthma from a tertiary referral center, the proportion of patients with an eosinophilic phenotype who would be eligible for mepolizumab, when stratified for the age of onset of asthma, and the prevalence of phenotypic features that favor mepolizumab therapy. Methods: An extensive database of 245 adults and children referred for severe asthma was used. The prevalence of severe asthma was estimated by using the European Respiratory Society/American Thoracic Society criteria. Patients with an eosinophilic uncontrolled phenotype qualified for mepolizumab. Results: In our cohort, 216 (88[%]) had severe asthma. Based on blood eosinophils of either greater than or equal to 150 cells/μL or greater than or